[S02DA03, antipyrine, Antipyrine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01GA01, streptomycin, Streptomycin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L04AA27, fingolimod, Digoxin may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, Succinylcholine may increase the arrhythmogenic activities of Digoxin.]
[A02BX02, sucralfate, Sucralfate can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01CG01, sulbactam, Sulbactam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01EC02, sulfadiazine, Sulfadiazine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, Sulfamethoxazole may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M04AB02, sulfinpyrazone, Digoxin may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Sulfisoxazole.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Digoxin.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L02BA01, tamoxifen, Tamoxifen may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01CB02, teniposide, Digoxin may decrease the cardiotoxic activities of Teniposide.]
[R03CC03, terbutaline, Terbutaline may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Dabigatran etexilate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Tetrabenazine.]
[S03AA02, tetracycline, The serum concentration of Digoxin can be increased when it is combined with Tetracycline.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Lurasidone.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Apomorphine.]
[L04AX02, thalidomide, Digoxin may decrease the cardiotoxic activities of Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Thiothixene.]
[C01BB04, aprindine, Digoxin may increase the arrhythmogenic activities of Aprindine.]
[G04BE06, moxisylyte, Moxisylyte may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AL03, tiapride, Tiapride may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01ED01, timolol, Timolol may increase the arrhythmogenic activities of Digoxin.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01AA12, tobramycin, Tobramycin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V04CA01, tolbutamide, Tolbutamide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02AX02, tramadol, The risk or severity of adverse effects can be increased when Tramadol is combined with Digoxin.]
[N06AX05, trazodone, The serum concentration of Digoxin can be increased when it is combined with Trazodone.]
[L01XF01, tretinoin, Digoxin may decrease the cardiotoxic activities of Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Digoxin.]
[C03DB02, triamterene, Triamterene may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the hypokalemic activities of Digoxin.]
[A16AX12, trientine, Triethylenetetramine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01BA09, clobetasone, The risk or severity of adverse effects can be increased when Clobetasone is combined with Digoxin.]
[S01BA10, alclometasone, The risk or severity of adverse effects can be increased when Alclometasone is combined with Digoxin.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Fluclorolone is combined with Digoxin.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Digoxin.]
[A03AA05, trimebutine, Digoxin may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Digoxin may increase the arrhythmogenic activities of Metipranolol.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Alimemazine.]
[N03AC02, trimethadione, Trimethadione may increase the arrhythmogenic activities of Digoxin.]
[J01EA01, trimethoprim, The serum concentration of Digoxin can be increased when it is combined with Trimethoprim.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Trimipramine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Triprolidine.]
[J01FA08, troleandomycin, The serum concentration of Digoxin can be increased when it is combined with Troleandomycin.]
[N06AX24, vilazodone, The serum concentration of Digoxin can be increased when it is combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of Cardiac Arrhythmia can be increased when Tubocurarine is combined with Digoxin.]
[R03DX07, roflumilast, Roflumilast may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01FX04, ipilimumab, Ipilimumab may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EX04, vandetanib, Vandetanib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R02AA14, oxyquinoline, Oxyquinoline may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A10BH05, linagliptin, Linagliptin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J05AP02, telaprevir, The serum concentration of Digoxin can be increased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Rilpivirine.]
[S01AA28, vancomycin, Vancomycin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N03AX21, ezogabine, Ezogabine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B01AF01, rivaroxaban, Rivaroxaban may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Indacaterol.]
[B01AC24, ticagrelor, The serum concentration of Digoxin can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Digoxin can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, Viloxazine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01CA01, vinblastine, Vinblastine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01CA02, vincristine, Digoxin may decrease the excretion rate of Vincristine which could result in a higher serum level.]
[L01CA03, vindesine, Digoxin may decrease the cardiotoxic activities of Vindesine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B01AA03, warfarin, Digoxin may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Zuclopenthixol.]
[J05AE02, indinavir, Indinavir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EC01, vemurafenib, The serum concentration of Digoxin can be increased when it is combined with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Digoxin.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B06AC02, icatibant, Icatibant may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Digoxin.]
[A02BC04, rabeprazole, The serum concentration of Digoxin can be increased when it is combined with Rabeprazole.]
[H05BX03, doxercalciferol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Doxercalciferol is combined with Digoxin.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Deferiprone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Digoxin.]
[G04BD07, tolterodine, Tolterodine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DH04, doripenem, Doripenem may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C07AB03, atenolol, Atenolol may increase the arrhythmogenic activities of Digoxin.]
[L03AB11, peginterferon alfa-2a, Digoxin may decrease the cardiotoxic activities of Peginterferon alfa-2a.]
[A11CC03, alfacalcidol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Alfacalcidol is combined with Digoxin.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of Cardiac Arrhythmia can be increased when Atracurium is combined with Digoxin.]
[S01FA01, atropine, Digoxin may increase the arrhythmogenic activities of Atropine.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Digoxin.]
[R07AX02, ivacaftor, Ivacaftor may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Prednylidene is combined with Digoxin.]
[B03XA04, peginesatide, Peginesatide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L04AX01, azathioprine, Azathioprine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Digoxin can be increased when it is combined with Avanafil.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01FD02, pertuzumab, Digoxin may decrease the cardiotoxic activities of Pertuzumab.]
[A08AA11, lorcaserin, Lorcaserin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G04BD12, mirabegron, The serum concentration of Digoxin can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, Carfilzomib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V03AX03, cobicistat, Cobicistat may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L02BB04, enzalutamide, The serum concentration of Digoxin can be increased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Digoxin.]
[L04AA31, teriflunomide, The excretion of Digoxin can be decreased when combined with Teriflunomide.]
[A02AA05, magnesium silicate, The serum concentration of Digoxin can be decreased when it is combined with Magnesium silicate.]
[A02AC02, calcium silicate, Calcium silicate may increase the arrhythmogenic activities of Digoxin.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Aldosterone is combined with Digoxin.]
[C01AA01, acetyldigitoxin, Digoxin may increase the arrhythmogenic activities of Acetyldigitoxin.]
[D02BA02, octinoxate, Octinoxate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Digoxin.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Digoxin.]
[S01GA07, brimonidine, Brimonidine may increase the bradycardic activities of Digoxin.]
[N04BD02, rasagiline, Rasagiline may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C08CA13, lercanidipine, Digoxin may increase the arrhythmogenic activities of Lercanidipine.]
[N06DA02, donepezil, Digoxin may increase the bradycardic activities of Donepezil.]
[L04AA29, tofacitinib, Digoxin may increase the bradycardic activities of Tofacitinib.]
[V09IX04, fluorodeoxyglucose F18, Fludeoxyglucose (18F) may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Pasireotide.]
[G04BE03, sildenafil, Sildenafil may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V08CA11, gadofosveset, Gadofosveset trisodium may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EA05, ponatinib, Ponatinib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B01AF02, apixaban, The serum concentration of Digoxin can be increased when it is combined with Apixaban.]
[A16AX08, teduglutide, Teduglutide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AX12, lomitapide, Lomitapide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Bedaquiline.]
[C04AX11, bencyclane, Digoxin may increase the arrhythmogenic activities of Bencyclane.]
[A10BH04, alogliptin, Alogliptin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Glycerol phenylbutyrate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the hypokalemic activities of Digoxin.]
[L04AX06, pomalidomide, Pomalidomide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A10BK02, canagliflozin, The serum concentration of Digoxin can be increased when it is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Gemifloxacin.]
[M04AB03, benzbromarone, Digoxin may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Moxifloxacin.]
[A06AX06, tegaserod, The serum concentration of Digoxin can be increased when it is combined with Tegaserod.]
[H03AA04, tiratricol, The serum concentration of Digoxin can be decreased when it is combined with Tiratricol.]
[J02AX04, caspofungin, The excretion of Caspofungin can be decreased when combined with Digoxin.]
[L03AA12, ancestim, Ancestim may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA18, everolimus, The serum concentration of Digoxin can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EE01, trametinib, Trametinib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[H05AA03, parathyroid hormone, The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Digoxin.]
[V09AX05, florbetapir F-18, Florbetapir (18F) may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EB03, afatinib, Afatinib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of hypotension can be increased when Levomilnacipran is combined with Digoxin.]
[J05AJ03, dolutegravir, The serum concentration of Digoxin can be increased when it is combined with Dolutegravir.]
[C08EA02, bepridil, Digoxin may increase the arrhythmogenic activities of Bepridil.]
[C02KX05, riociguat, The serum concentration of Digoxin can be increased when it is combined with Riociguat.]
[A10BJ03, lixisenatide, Lixisenatide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A05AA03, cholic acid, Cholic Acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02KX04, macitentan, Macitentan may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AX26, vortioxetine, Vortioxetine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J05AP08, sofosbuvir, Sofosbuvir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Droxidopa may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C07AB04, acebutolol, Digoxin may increase the arrhythmogenic activities of Acebutolol.]
[N05CH03, tasimelteon, Tasimelteon may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L04AA32, apremilast, Apremilast may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L02BG02, formestane, Formestane may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Digoxin.]
[S01ED02, betaxolol, Betaxolol may increase the arrhythmogenic activities of Digoxin.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AB02, bezafibrate, The excretion of Digoxin can be decreased when combined with Bezafibrate.]
[L01ED02, ceritinib, Digoxin may increase the bradycardic activities of Ceritinib.]
[B01AC26, vorapaxar, Vorapaxar may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A03BA03, hyoscyamine, Digoxin may increase the arrhythmogenic activities of Hyoscyamine.]
[L01XH04, belinostat, The serum concentration of Digoxin can be increased when it is combined with Belinostat.]
[L01EM01, idelalisib, The serum concentration of Digoxin can be increased when it is combined with Idelalisib.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Olodaterol.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V03AE01, polystyrene sulfonate, The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Digoxin.]
[D11AA01, glycopyrronium, The serum concentration of Digoxin can be increased when it is combined with Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05CM19, suvorexant, Suvorexant may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A16AX10, eliglustat, The serum concentration of Digoxin can be increased when it is combined with Eliglustat.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EX09, nintedanib, The serum concentration of Digoxin can be increased when it is combined with Nintedanib.]
[S03AA06, gentamicin, The serum concentration of Digoxin can be increased when it is combined with Gentamicin.]
[J05AP09, dasabuvir, The serum concentration of Digoxin can be increased when it is combined with Dasabuvir.]
[B01AF03, edoxaban, Edoxaban may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Digoxin.]
[L01EF01, palbociclib, Palbociclib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Digoxin.]
[J05AP07, daclatasvir, Daclatasvir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01EB17, ivabradine, Ivabradine may increase the bradycardic activities of Digoxin.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J05AP06, asunaprevir, The serum concentration of Digoxin can be increased when it is combined with Asunaprevir.]
[A07DA06, eluxadoline, The serum concentration of Eluxadoline can be increased when it is combined with Digoxin.]
[A04AD14, rolapitant, Rolapitant may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G02CX02, flibanserin, Flibanserin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A06AD03, magnesium peroxide, The serum concentration of Digoxin can be decreased when it is combined with Magnesium peroxide.]
[A10BF01, acarbose, The serum concentration of Digoxin can be decreased when it is combined with Acarbose.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC03, lansoprazole, The serum concentration of Digoxin can be increased when it is combined with Lansoprazole.]
[V03AB37, idarucizumab, Idarucizumab may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J02AC05, isavuconazole, The serum concentration of Digoxin can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Digoxin.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Digoxin.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Digoxin.]
[L01XG03, ixazomib, Ixazomib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B01AC27, selexipag, The serum concentration of Digoxin can be increased when it is combined with Selexipag.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Digoxin.]
[M04AB05, lesinurad, Lesinurad may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J05AP10, elbasvir, The serum concentration of Digoxin can be increased when it is combined with Elbasvir.]
[J05AP11, grazoprevir, The serum concentration of Digoxin can be increased when it is combined with Grazoprevir.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A02AB06, aloglutamol, The serum concentration of Digoxin can be decreased when it is combined with Aloglutamol.]
[N02BA02, aloxiprin, The serum concentration of Digoxin can be decreased when it is combined with Aloxiprin.]
[N03AX23, brivaracetam, Brivaracetam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01XX52, venetoclax, Venetoclax may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05BA08, bromazepam, Bromazepam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A02AD05, aluminum magnesium silicate, Almasilate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A02AB03, aluminum phosphate, The serum concentration of Digoxin can be decreased when it is combined with Aluminium phosphate.]
[D07AC11, amcinonide, The risk or severity of adverse effects can be increased when Amcinonide is combined with Digoxin.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Dexbrompheniramine.]
[C08CA01, amlodipine, Amlodipine may increase the arrhythmogenic activities of Digoxin.]
[C03CA02, bumetanide, The risk or severity of adverse effects can be increased when Bumetanide is combined with Digoxin.]
[N01BB01, bupivacaine, Levobupivacaine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C07AA19, bupranolol, Digoxin may increase the arrhythmogenic activities of Bupranolol.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Buserelin.]
[N05BE01, buspirone, Buspirone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01AB01, busulfan, Digoxin may decrease the cardiotoxic activities of Busulfan.]
[L01XX27, arsenic trioxide, Arsenic trioxide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06DA03, rivastigmine, Digoxin may increase the bradycardic activities of Rivastigmine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Artemether.]
[M02AA03, clofezone, The serum concentration of Digoxin can be increased when it is combined with Rabeprazole.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Azatadine.]
[S01AA26, azithromycin, The serum concentration of Digoxin can be increased when it is combined with Azithromycin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A06AH05, naldemedine, Naldemedine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Deutetrabenazine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02BF02, pregabalin, Pregabalin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C09AA07, benazepril, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Benazepril.]
[H05BX05, calcifediol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Calcifediol is combined with Digoxin.]
[D05AX03, calcitriol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Calcitriol is combined with Digoxin.]
[A12AA04, calcium carbonate, Calcium carbonate may increase the arrhythmogenic activities of Digoxin.]
[P01CA02, benznidazole, Benznidazole may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G04BA03, calcium chloride, Calcium chloride may increase the arrhythmogenic activities of Digoxin.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J05AE09, tipranavir, Tipranavir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[D11AX03, calcium gluconate, Calcium gluconate may increase the arrhythmogenic and cardiotoxic activities of Digoxin.]
[H03BA03, benzylthiouracil, The serum concentration of Digoxin can be increased when it is combined with Benzylthiouracil.]
[N07XX13, valbenazine, Valbenazine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A12AA01, calcium phosphate, Calcium Phosphate may increase the arrhythmogenic activities of Digoxin.]
[J01MA23, delafloxacin, Delafloxacin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B01AF04, betrixaban, The serum concentration of Digoxin can be increased when it is combined with Betrixaban.]
[P03AC02, bioallethrin, Digoxin may increase the arrhythmogenic activities of Bioallethrin.]
[L01BC06, capecitabine, Capecitabine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01XX59, enasidenib, Enasidenib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EH02, neratinib, Neratinib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Digoxin.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Vorinostat.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Digoxin.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Digoxin.]
[A02BX12, bismuth subnitrate, The serum concentration of Digoxin can be decreased when it is combined with Bismuth subnitrate.]
[C07AB07, bisoprolol, The therapeutic efficacy of Digoxin can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, Digoxin may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C07AA17, bopindolol, Bopindolol may increase the bradycardic activities of Digoxin.]
[V03AB23, acetylcysteine, The excretion of Digoxin can be decreased when combined with Acetylcysteine.]
[C03DA03, canrenone, Canrenone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Budesonide is combined with Digoxin.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Butriptyline.]
[C01AA02, acetyldigoxins, Digoxin may increase the arrhythmogenic activities of Acetyldigoxin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, Acrivastine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C09AA01, captopril, The serum concentration of Digoxin can be increased when it is combined with Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Digoxin can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, Digoxin may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A06AC08, calcium polycarbophil, Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Digoxin.]
[H03BB01, carbimazole, The serum concentration of Digoxin can be increased when it is combined with Carbimazole.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Carbinoxamine.]
[C07AG02, carvedilol, The serum concentration of Digoxin can be increased when it is combined with Carvedilol.]
[B02BX08, avatrombopag, The serum concentration of Digoxin can be increased when it is combined with Avatrombopag.]
[L04AA37, baricitinib, Baricitinib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Encorafenib.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Digoxin.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01GB14, plazomicin, Plazomicin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C07AB08, celiprolol, Digoxin may increase the arrhythmogenic activities of Celiprolol.]
[H01CC03, elagolix, Elagolix may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Ivosidenib.]
[P01BA07, tafenoquine, The serum concentration of Digoxin can be increased when it is combined with Tafenoquine.]
[A16AX14, migalastat, Migalastat may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N03AX17, stiripentol, The excretion of Digoxin can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Digoxin can be increased when it is combined with Lusutrombopag.]
[J01AA13, eravacycline, Eravacycline can cause an increase in the absorption of Digoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L01EM04, duvelisib, The serum concentration of Digoxin can be increased when it is combined with Duvelisib.]
[L01EB07, dacomitinib, Dacomitinib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01AA14, sarecycline, Sarecycline may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01AA15, omadacycline, Omadacycline can cause an increase in the absorption of Digoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[D08AE05, chloroxylenol, Chloroxylenol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Digoxin.]
[R03BB08, revefenacin, Digoxin may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01ED05, lorlatinib, Lorlatinib may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EX12, larotrectinib, The serum concentration of Digoxin can be increased when it is combined with Larotrectinib.]
[L01EX13, gilteritinib, The serum concentration of Digoxin can be increased when it is combined with Gilteritinib.]
[L01XJ03, glasdegib, Glasdegib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Amifampridine.]
[A06AX05, prucalopride, Prucalopride may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01BG07, cifenline, Digoxin may increase the arrhythmogenic activities of Cibenzoline.]
[C09AA08, cilazapril, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Cilazapril.]
[B01AC23, cilostazol, Cilostazol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01ED05, carteolol, Digoxin may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Triclabendazole.]
[J01FA09, clarithromycin, The serum concentration of Digoxin can be increased when it is combined with Clarithromycin.]
[N06BA14, solriamfetol, Solriamfetol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EN01, erdafitinib, The serum concentration of Digoxin can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, Clobazam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[D07AB21, clocortolone, The risk or severity of adverse effects can be increased when Clocortolone is combined with Digoxin.]
[J01AA11, clomocycline, Clomocycline can cause an increase in the absorption of Digoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Cloprednol is combined with Digoxin.]
[V03AE07, calcium acetate, Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Digoxin.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Candesartan.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Cortivazol is combined with Digoxin.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L02BB06, darolutamide, The serum concentration of Digoxin can be increased when it is combined with Darolutamide.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EX15, pexidartinib, The excretion of Digoxin can be decreased when combined with Pexidartinib.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C03BX03, cicletanine, Digoxin may increase the arrhythmogenic activities of Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EJ02, fedratinib, Fedratinib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Entrectinib.]
[N07XX11, pitolisant, Digoxin may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Digoxin.]
[N04CX01, istradefylline, The serum concentration of Digoxin can be increased when it is combined with Istradefylline.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the hypokalemic activities of Digoxin.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Deflazacort is combined with Digoxin.]
[L01FD01, trastuzumab, Digoxin may decrease the cardiotoxic activities of Trastuzumab.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Digoxin.]
[N02CC08, lasmiditan, The serum concentration of Digoxin can be increased when it is combined with Lasmiditan.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M09AX08, golodirsen, Golodirsen may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02CD04, ubrogepant, The serum concentration of Digoxin can be increased when it is combined with Ubrogepant.]
[L01FX13, enfortumab vedotin, The serum concentration of Digoxin can be increased when it is combined with Enfortumab vedotin.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Dexbrompheniramine.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Dexpanthenol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05CM21, lemborexant, The serum concentration of Digoxin can be increased when it is combined with Lemborexant.]
[L01XX72, tazemetostat, The serum concentration of Digoxin can be increased when it is combined with Tazemetostat.]
[N02CD06, rimegepant, The serum concentration of Digoxin can be increased when it is combined with Rimegepant.]
[C10AX15, bempedoic acid, The excretion of Digoxin can be decreased when combined with Bempedoic acid.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Gatifloxacin.]
[J05AE05, amprenavir, The excretion of Digoxin can be decreased when combined with Amprenavir.]
[L01EE04, selumetinib, The serum concentration of Digoxin can be increased when it is combined with Selumetinib.]
[R02AA03, dichlorobenzyl alcohol, Dichlorobenzyl alcohol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G03DB08, dienogest, Dienogest may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[D07AC19, difluprednate, The risk or severity of adverse effects can be increased when Difluprednate is combined with Digoxin.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C08CA16, clevidipine, Digoxin may increase the arrhythmogenic activities of Clevidipine.]
[C01BD07, dronedarone, Digoxin may increase the atrioventricular blocking (AV block) activities of Dronedarone.]
[J01FA13, dirithromycin, The serum concentration of Digoxin can be increased when it is combined with Dirithromycin.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Chlorcyclizine.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EX17, capmatinib, The serum concentration of Digoxin can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Fluprednidene is combined with Digoxin.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EX19, ripretinib, Ripretinib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V08CA05, mangafodipir, Mangafodipir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01BA14, loteprednol, The risk or severity of adverse effects can be increased when Loteprednol is combined with Digoxin.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C08CA17, levamlodipine, The serum concentration of Digoxin can be increased when it is combined with Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Fostemsavir.]
[L01FX15, belantamab mafodotin, Digoxin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[P01BA01, chloroquine, Chloroquine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the hypokalemic activities of Digoxin.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Chlorprothixene.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digoxin.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A11CC05, cholecalciferol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Cholecalciferol is combined with Digoxin.]
[V04CK02, cholecystokinin, The excretion of Cholecystokinin can be decreased when combined with Digoxin.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AC01, cholestyramine resin, The serum concentration of Digoxin can be decreased when it is combined with Cholestyramine.]
[N02BA03, choline salicylate, Choline salicylate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06BX18, vinpocetine, Digoxin may increase the arrhythmogenic activities of Vinpocetine.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B06AC06, berotralstat, The serum concentration of Digoxin can be increased when it is combined with Berotralstat.]
[A16AX20, lonafarnib, Lonafarnib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M09AA01, hydroquinine, Digoxin may increase the arrhythmogenic activities of Hydroquinine.]
[L01BB05, fludarabine, Digoxin may decrease the cardiotoxic activities of Fludarabine.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Relugolix.]
[M01AX25, chondroitin sulfates, Chondroitin sulfate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L04AD03, voclosporin, The serum concentration of Digoxin can be increased when it is combined with Voclosporin.]
[L01EX21, tepotinib, The serum concentration of Digoxin can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, Umbralisib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V03AF12, trilaciclib, The serum concentration of Digoxin can be increased when it is combined with Trilaciclib.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Felbamate.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Flumequine.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Digoxin.]
[S01JA01, fluorescein, Digoxin may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[N02BG07, flupirtine, Flupirtine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Digoxin.]
[S01LA08, bevacizumab, Digoxin may decrease the cardiotoxic activities of Bevacizumab.]
[L01EK03, tivozanib, The serum concentration of Digoxin can be increased when it is combined with Tivozanib.]
[L01FX22, loncastuximab tesirine, The serum concentration of Digoxin can be increased when it is combined with Loncastuximab tesirine.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N07CA02, cinnarizine, Digoxin may increase the arrhythmogenic activities of Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Digoxin can be increased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, Ciprofloxacin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01XA01, cisplatin, Cisplatin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA48, belumosudil, Belumosudil may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Digoxin is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Mobocertinib.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Digoxin.]
[V09AB03, ioflupane I-123, Ioflupane I-123 may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Technetium Tc-99m exametazime may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Digoxin can be increased when it is combined with Technetium Tc-99m sestamibi.]
[V09AX06, florbetaben f-18, Florbetaben (18F) may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Clemastine.]
[A10BB12, glimepiride, Glimepiride may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A12AA02, calcium glubionate, Calcium glubionate anhydrous may increase the arrhythmogenic and cardiotoxic activities of Digoxin.]
[J01FF01, clindamycin, The serum concentration of Digoxin can be increased when it is combined with Clindamycin.]
[N06AX25, St. John's wort extract, The serum concentration of Digoxin can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Digoxin can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Digoxin can be increased when it is combined with Maribavir.]
[D07AD01, clobetasol, The risk or severity of adverse effects can be increased when Clobetasol is combined with Digoxin.]
[D11AH08, abrocitinib, The serum concentration of Digoxin can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, Clofazimine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B06AX04, mitapivat, The serum concentration of Digoxin can be increased when it is combined with Mitapivat.]
[N01BB10, levobupivacaine, Levobupivacaine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EJ03, pacritinib, The serum concentration of Digoxin can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Digoxin can be increased when it is combined with Clomifene.]
[N06AA04, clomipramine, Clomipramine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N03AE01, clonazepam, Clonazepam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01EA04, clonidine, Clonidine may increase the atrioventricular blocking (AV block) activities of Digoxin.]
[J05AB17, brincidofovir, The serum concentration of Brincidofovir can be increased when it is combined with Digoxin.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[A05BA08, glycyrrhizic acid, Digoxin may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Granisetron.]
[N05AH02, clozapine, Clozapine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EN04, futibatinib, The serum concentration of Digoxin can be increased when it is combined with Futibatinib.]
[A10BK06, sotagliflozin, The serum concentration of Digoxin can be increased when it is combined with Sotagliflozin.]
[J01GB12, arbekacin, Arbekacin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[D07AC12, halometasone, The risk or severity of adverse effects can be increased when Halometasone is combined with Digoxin.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Cocaine.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M04AC01, colchicine, Colchicine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AC02, colestipol, The serum concentration of Digoxin can be decreased when it is combined with Colestipol.]
[J01XB01, colistin, Colistin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A07BA01, activated charcoal, Activated charcoal may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA13, hydroquinidine, Digoxin may increase the arrhythmogenic activities of Hydroquinidine.]
[A02AD04, hydrotalcite, The serum concentration of Digoxin can be decreased when it is combined with Hydrotalcite.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Desflurane.]
[A04AA03, tropisetron, Digoxin may increase the arrhythmogenic activities of Tropisetron.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01FA15, telithromycin, The serum concentration of Digoxin can be increased when it is combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Ciclesonide is combined with Digoxin.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Desloratadine.]
[J05AB14, valganciclovir, Valganciclovir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C05BB03, invert sugar, Invert sugar may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V08AB09, iodixanol, Iodixanol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V08AB05, iopromide, Iopromide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V08AB07, ioversol, Ioversol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V08AB12, ioxilan, Ioxilan may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02CC05, almotriptan, Almotriptan may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J02AC02, itraconazole, The serum concentration of Digoxin can be increased when it is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Bemiparin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Emedastine.]
[N05BA10, ketazolam, Ketazolam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Posaconazole.]
[A02BC05, esomeprazole, The serum concentration of Digoxin can be increased when it is combined with Esomeprazole.]
[C08CA09, lacidipine, Digoxin may increase the arrhythmogenic activities of Lacidipine.]
[N03AX09, lamotrigine, Digoxin may increase the arrhythmogenic activities of Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Levocabastine.]
[S01BA03, cortisone, The risk or severity of adverse effects can be increased when Cortisone is combined with Digoxin.]
[N07BC04, lofexidine, Lofexidine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Lomefloxacin.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R06AX13, loratadine, Digoxin may decrease the excretion rate of Loratadine which could result in a higher serum level.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A02AD02, magaldrate, The serum concentration of Digoxin can be decreased when it is combined with Magaldrate.]
[A06AD01, magnesium carbonate, Magnesium carbonate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C08CA11, manidipine, Digoxin may increase the arrhythmogenic activities of Manidipine.]
[S01BA08, medrysone, The risk or severity of adverse effects can be increased when Medrysone is combined with Digoxin.]
[C07AA14, mepindolol, Mepindolol may increase the bradycardic activities of Digoxin.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Meprednisone is combined with Digoxin.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Mequitazine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of adverse effects can be increased when Digoxin is combined with Adenosine.]
[C04AX01, cyclandelate, Digoxin may increase the arrhythmogenic activities of Cyclandelate.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Cyclizine.]
[C03DA04, eplerenone, Eplerenone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AD03, metylperon, Digoxin may increase the arrhythmogenic activities of Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the hypokalemic activities of Digoxin.]
[J01FA03, midecamycin, The serum concentration of Digoxin can be increased when it is combined with Midecamycin.]
[A10BF02, miglitol, The serum concentration of Digoxin can be decreased when it is combined with Miglitol.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01AA01, cyclophosphamide, Digoxin may decrease the cardiotoxic activities of Cyclophosphamide.]
[S01XA18, cyclosporine, The serum concentration of Digoxin can be increased when it is combined with Cyclosporine.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Moexipril.]
[C10AA07, rosuvastatin, Digoxin may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C03XA02, conivaptan, The serum concentration of Digoxin can be increased when it is combined with Conivaptan.]
[G04BE09, vardenafil, Vardenafil may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M01AH05, etoricoxib, Etoricoxib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Digoxin.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Dantrolene.]
[L01DB02, daunorubicin, Digoxin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N07BB05, nalmefene, Nalmefene may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Digoxin.]
[J01AA01, demeclocycline, Demeclocycline can cause an increase in the absorption of Digoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C07AB12, nebivolol, Digoxin may increase the arrhythmogenic activities of Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AX06, nefazodone, The serum concentration of Digoxin can be increased when it is combined with Nefazodone.]
[C01DX16, nicorandil, Digoxin may increase the arrhythmogenic activities of Nicorandil.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01CA23, theodrenaline, The risk or severity of Cardiac Arrhythmia can be increased when Theodrenaline is combined with Digoxin.]
[M03AC11, cisatracurium, The risk or severity of Cardiac Arrhythmia can be increased when Cisatracurium is combined with Digoxin.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Solifenacin.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AA01, desipramine, Desipramine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01AA07, deslanoside, Digoxin may increase the arrhythmogenic activities of Deslanoside.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01BA11, desonide, The risk or severity of adverse effects can be increased when Desonide is combined with Digoxin.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Digoxin.]
[V04CH02, indigo carmine, Indigotindisulfonic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[H02AA03, desoxycorticosterone, The risk or severity of adverse effects can be increased when Desoxycortone is combined with Digoxin.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C09XA02, aliskiren, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Oxaliplatin.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Dexamethasone is combined with Digoxin.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[H05AA02, teriparatide, The risk or severity of adverse effects can be increased when Teriparatide is combined with Digoxin.]
[P03AC04, permethrin, Permethrin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R05DA08, pholcodine, Pholcodine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The serum concentration of Digoxin can be increased when it is combined with Diclofenac.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A03AX04, pinaverium, Digoxin may increase the arrhythmogenic activities of Pinaverium.]
[L01DC04, ixabepilone, The serum concentration of Digoxin can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Erlotinib.]
[C03CA03, piretanide, The risk or severity of adverse effects can be increased when Piretanide is combined with Digoxin.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Digoxin.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Digoxin.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01AA04, digitoxin, Digoxin may increase the arrhythmogenic activities of Digitoxin.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Pipemidic acid.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Digoxin.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01DA05, pentaerythritol tetranitrate, Pentaerythritol tetranitrate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AX09, ezetimibe, Digoxin may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[C04AE04, dihydroergocristine, Digoxin may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L04AX04, lenalidomide, The serum concentration of Digoxin can be increased when it is combined with Lenalidomide.]
[A11CC02, dihydrotachysterol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Digoxin.]
[J05AE08, atazanavir, Atazanavir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Digoxin.]
[H03BC01, potassium perchlorate, Potassium perchlorate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[D07AC18, prednicarbate, The risk or severity of adverse effects can be increased when Prednicarbate is combined with Digoxin.]
[C08DB01, diltiazem, The serum concentration of Digoxin can be increased when it is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Dimercaprol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Dimethyl sulfoxide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Digoxin.]
[C05CA03, diosmin, Diosmin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The serum concentration of Digoxin can be increased when it is combined with Diphenoxylate.]
[C09AA06, quinapril, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Quinapril.]
[B01AC07, dipyridamole, Digoxin may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of hyperkalemia can be increased when Ramipril is combined with Digoxin.]
[S01XA23, sirolimus, The serum concentration of Digoxin can be increased when it is combined with Sirolimus.]
[S01AX06, resorcinol, Resorcinol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01BA03, disopyramide, Disopyramide may increase the arrhythmogenic activities of Digoxin.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Disulfiram.]
[S02AA12, rifamycin SV, Rifamycin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Risperidone.]
[R06AE09, levocetirizine, Levocetirizine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N01BB09, ropivacaine, Ropivacaine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Sunitinib.]
[C03XA01, tolvaptan, The serum concentration of Digoxin can be increased when it is combined with Tolvaptan.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Digoxin.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02KX02, ambrisentan, The serum concentration of Digoxin can be increased when it is combined with Ambrisentan.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Salmeterol.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Domperidone.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Dosulepin.]
[N06AA12, doxepin, Doxepin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01DB01, doxorubicin, Digoxin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Digoxin.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Droperidol.]
[A08AA10, sibutramine, Sibutramine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AA01, simvastatin, The serum concentration of Digoxin can be increased when it is combined with Simvastatin.]
[B05XA02, sodium bicarbonate, The serum concentration of Digoxin can be decreased when it is combined with Sodium bicarbonate.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Digoxin.]
[A12CA02, sodium sulfate, Sodium sulfate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C09AA11, spirapril, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Spirapril.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Sultopride.]
[N02CC01, sumatriptan, Sumatriptan may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V04CX07, edrophonium, Edrophonium may increase the atrioventricular blocking (AV block) and arrhythmogenic activities of Digoxin.]
[C07AB13, talinolol, Digoxin may increase the arrhythmogenic activities of Talinolol.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Corticotropin is combined with Digoxin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Temafloxacin.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G04BD05, terodiline, Digoxin may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, Digoxin may increase the arrhythmogenic activities of Tertatolol.]
[C09AA02, enalapril, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Enalapril.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AG03, toloxatone, Toloxatone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L02BA02, toremifene, Toremifene may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01AA12, tigecycline, Tigecycline can cause an increase in the absorption of Digoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C09AA10, trandolapril, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Trandolapril.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Digoxin.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Triptorelin.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Enoxacin.]
[L01CA04, vinorelbine, Digoxin may decrease the cardiotoxic activities of Vinorelbine.]
[S01FB02, ephedrine, The risk or severity of Cardiac Arrhythmia can be increased when Ephedrine is combined with Digoxin.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Epinastine.]
[N06AX16, venlafaxine, Venlafaxine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01GA03, xylometazoline, Digoxin may increase the arrhythmogenic activities of Xylometazoline.]
[C08CA12, mepirodipine, Digoxin may increase the arrhythmogenic activities of Barnidipine.]
[S01EA01, epinephrine, The risk or severity of Cardiac Arrhythmia can be increased when Epinephrine is combined with Digoxin.]
[L01DB03, epirubicin, Digoxin may decrease the cardiotoxic activities of Epirubicin.]
[C09AA15, zofenopril, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Zofenopril.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N03AX15, zonisamide, Digoxin may increase the arrhythmogenic activities of Zonisamide.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02AC02, guanfacine, Guanfacine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01BG01, moricizine, Digoxin may increase the arrhythmogenic activities of Moricizine.]
[A11CC01, ergocalciferol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Digoxin.]
[L03AX05, pidotimod, Pidotimod may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01AA17, erythromycin, The serum concentration of Digoxin can be increased when it is combined with Erythromycin.]
[N05CD04, estazolam, Estazolam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Digoxin.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Fluticasone is combined with Digoxin.]
[C10AA04, fluvastatin, The excretion of Fluvastatin can be decreased when combined with Digoxin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[D07AC21, halobetasol, The risk or severity of adverse effects can be increased when Ulobetasol is combined with Digoxin.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01BD05, ibutilide, Ibutilide may increase the arrhythmogenic activities of Digoxin.]
[N03AD01, ethosuximide, Digoxin may increase the arrhythmogenic activities of Ethosuximide.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Digoxin.]
[C01BA05, ajmaline, Digoxin may increase the arrhythmogenic activities of Ajmaline.]
[L04AD02, tacrolimus, Tacrolimus may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Fleroxacin.]
[R06AX11, astemizole, Digoxin may decrease the excretion rate of Astemizole which could result in a higher serum level.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Terfenadine.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AX12, bupropion, Bupropion may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AB08, fluvoxamine, Fluvoxamine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01BB03, tocainide, Digoxin may increase the arrhythmogenic activities of Tocainide.]
[C01BC08, encainide, Digoxin may increase the arrhythmogenic activities of Encainide.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Sodium aurothiomalate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B05AA05, dextran, Dextran may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Famotidine.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C08CA02, felodipine, Digoxin may increase the arrhythmogenic activities of Felodipine.]
[C08EA01, fendiline, Digoxin may increase the arrhythmogenic activities of Fendiline.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02AB03, fentanyl, Fentanyl may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R03CC02, albuterol, The serum concentration of Digoxin can be decreased when it is combined with Salbutamol.]
[L01BB06, clofarabine, Clofarabine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L04AA40, cladribine, Digoxin may decrease the cardiotoxic activities of Cladribine.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G04BD02, flavoxate, Flavoxate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01BC04, flecainide, The serum concentration of Digoxin can be increased when it is combined with Flecainide.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01CF05, floxacillin, Flucloxacillin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J02AC01, fluconazole, Fluconazole may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Digoxin.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[D07XB01, flumethasone, The risk or severity of adverse effects can be increased when Flumethasone is combined with Digoxin.]
[N07CA03, flunarizine, Digoxin may increase the arrhythmogenic activities of Flunarizine.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Digoxin.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Fluocortolone is combined with Digoxin.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Digoxin.]
[L01BC02, fluorouracil, Digoxin may decrease the cardiotoxic activities of Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Digoxin.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Flupentixol.]
[D07AC07, flurandrenolide, The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Digoxin.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AG01, fluspirilene, Digoxin may increase the arrhythmogenic activities of Fluspirilene.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01BC03, tegafur, Tegafur may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M03AA01, alcuronium, The risk or severity of Cardiac Arrhythmia can be increased when Alcuronium is combined with Digoxin.]
[J05AE10, darunavir, The serum concentration of Digoxin can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of adverse effects can be increased when Furosemide is combined with Digoxin.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Galantamine.]
[M03AC02, gallamine, The risk or severity of Cardiac Arrhythmia can be increased when Gallamine is combined with Digoxin.]
[C08DA02, gallopamil, Digoxin may increase the arrhythmogenic activities of Gallopamil.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AB04, gemfibrozil, Gemfibrozil may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01XA03, telavancin, Telavancin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Dasatinib.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Digoxin.]
[J05AG04, etravirine, The serum concentration of Digoxin can be increased when it is combined with Etravirine.]
[A12AA13, calcium citrate, Calcium citrate may increase the arrhythmogenic activities of Digoxin.]
[A12AA10, calcium gluceptate, Calcium glucoheptonate may increase the arrhythmogenic and cardiotoxic activities of Digoxin.]
[A12AA05, calcium lactate, Calcium lactate may increase the arrhythmogenic and cardiotoxic activities of Digoxin.]
[A12AA30, calcium levulinate, Calcium levulinate may increase the arrhythmogenic and cardiotoxic activities of Digoxin.]
[N03AD03, methsuximide, Digoxin may increase the arrhythmogenic activities of Methsuximide.]
[N01AH02, alfentanil, Digoxin may increase the bradycardic activities of Alfentanil.]
[L01EH01, lapatinib, The bioavailability of Digoxin can be increased when combined with Lapatinib.]
[A10BB01, glyburide, Glyburide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A10BB07, glipizide, Glipizide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Dexmedetomidine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B05CX03, glycine, The risk or severity of adverse effects can be increased when Glycine is combined with Digoxin.]
[C01BD04, dofetilide, The risk or severity of torsade de pointes can be increased when Dofetilide is combined with Digoxin.]
[H01AB01, thyrotropin alfa, The serum concentration of Digoxin can be decreased when it is combined with Thyrotropin alfa.]
[L01EX02, sorafenib, Sorafenib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C07AB09, esmolol, Esmolol may increase the arrhythmogenic activities of Digoxin.]
[M01CB04, aurothioglucose, Aurothioglucose may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01LA03, pegaptanib, Pegaptanib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01EX01, guanethidine, Guanethidine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Halofantrine.]
[D07AD02, halcinonide, The risk or severity of adverse effects can be increased when Halcinonide is combined with Digoxin.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Histrelin.]
[N05AH04, quetiapine, Quetiapine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06BX13, idebenone, Idebenone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01CE02, irinotecan, The excretion of Digoxin can be decreased when combined with Irinotecan.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C09CA01, losartan, Digoxin may increase the arrhythmogenic activities of Losartan.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Heparin.]
[G03DC01, allylestrenol, Allylestrenol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C08CA10, nilvadipine, Digoxin may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Oxatomide.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB02, hydralazine, Hydralazine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the hypokalemic activities of Digoxin.]
[S02BA01, hydrocortisone, The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Digoxin.]
[D07AC16, hydrocortisone aceponate, The risk or severity of adverse effects can be increased when Hydrocortisone aceponate is combined with Digoxin.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the hypokalemic activities of Digoxin.]
[B05XA17, potassium acetate, Potassium acetate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Digoxin.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G04BD06, propiverine, Propiverine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Hydroxychloroquine.]
[B05AA07, hetastarch, Hydroxyethyl Starch may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Hydroxyzine.]
[S01BA13, rimexolone, The risk or severity of adverse effects can be increased when Rimexolone is combined with Digoxin.]
[R02AX02, ibuprofen, The serum concentration of Digoxin can be increased when it is combined with Ibuprofen.]
[B05XA08, sodium acetate, Sodium acetate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01DB06, idarubicin, Digoxin may decrease the cardiotoxic activities of Idarubicin.]
[L01AA06, ifosfamide, Ifosfamide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N01AH03, sufentanil, Digoxin may increase the bradycardic activities of Sufentanil.]
[N06AA02, imipramine, Imipramine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01CD01, paclitaxel, Paclitaxel may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Terlipressin.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Tixocortol is combined with Digoxin.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Tizanidine.]
[L01CE01, topotecan, Topotecan may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C03BA11, indapamide, Indapamide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01BC01, indomethacin, The serum concentration of Digoxin can be increased when it is combined with Indomethacin.]
[A11HA07, inositol, Inositol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of hypotension can be increased when Milnacipran is combined with Digoxin.]
[S01XA28, varenicline, Varenicline may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A10BH01, sitagliptin, Sitagliptin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05BA12, alprazolam, The serum concentration of Digoxin can be increased when it is combined with Alprazolam.]
[N05CH02, ramelteon, Ramelteon may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Digoxin.]
[C10AA06, cerivastatin, Digoxin may decrease the excretion rate of Cerivastatin which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Anagrelide.]
[C07AA01, alprenolol, Digoxin may increase the arrhythmogenic activities of Alprenolol.]
[C03BA02, quinethazone, The risk or severity of adverse effects can be increased when Quinethazone is combined with Digoxin.]
[V03AB01, ipecac, Ipecac may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C09AA16, imidapril, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Isoflurane.]
[J04AC01, isoniazid, Isoniazid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J05AX05, inosine pranobex, Inosine pranobex may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A10BJ01, exenatide, The serum concentration of Digoxin can be decreased when it is combined with Exenatide.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[P02CF01, ivermectin, The excretion of Digoxin can be decreased when combined with Ivermectin.]
[J01FA07, josamycin, The serum concentration of Digoxin can be increased when it is combined with Josamycin.]
[S01AA24, kanamycin, Kanamycin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A07BC02, kaolin, The serum concentration of Digoxin can be decreased when it is combined with Kaolin.]
[A02AB01, aluminum hydroxide, The serum concentration of Digoxin can be decreased when it is combined with Aluminum hydroxide.]
[N01AX03, ketamine, Ketamine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B01AC22, prasugrel, Prasugrel may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J02AB02, ketoconazole, The serum concentration of Digoxin can be increased when it is combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Digoxin.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Mizolastine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C07AG01, labetalol, Labetalol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N04BB01, amantadine, Amantadine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N03AX18, lacosamide, Digoxin may increase the bradycardic activities of Lacosamide.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digoxin.]
[L01DC03, mitomycin, Digoxin may decrease the cardiotoxic activities of Mitomycin.]
[S02DA01, lidocaine, Lidocaine may increase the arrhythmogenic activities of Digoxin.]
[C08EX01, lidoflazine, Digoxin may increase the arrhythmogenic activities of Lidoflazine.]
[S01AA21, amikacin, Amikacin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A07DA03, loperamide, Digoxin may increase the arrhythmogenic activities of Loperamide.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AH01, loxapine, Loxapine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01AA04, lymecycline, Lymecycline can cause an increase in the absorption of Digoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L01EG01, temsirolimus, The serum concentration of Digoxin can be increased when it is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Magnesium chloride may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A12CC10, magnesium oxide, The serum concentration of Digoxin can be decreased when it is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, Digoxin may increase the arrhythmogenic activities of Magnesium sulfate.]
[L01BA05, pralatrexate, Pralatrexate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EA03, nilotinib, Nilotinib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V04CX04, mannitol, Mannitol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AA21, maprotiline, Maprotiline may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01AA05, mechlorethamine, Digoxin may decrease the cardiotoxic activities of Mechlorethamine.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01AA08, medigoxin, Digoxin may increase the arrhythmogenic activities of Metildigoxin.]
[P01BC02, mefloquine, Mefloquine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Dalteparin.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02AB02, meperidine, Meperidine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N01BB03, mepivacaine, Mepivacaine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G04BX16, tiopronin, Tiopronin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Mesoridazine.]
[N05AX13, paliperidone, Paliperidone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A10BA02, metformin, The serum concentration of Digoxin can be increased when it is combined with Metformin.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Dolasetron.]
[H01CB03, lanreotide, Digoxin may increase the bradycardic activities of Lanreotide.]
[J01AA05, methacycline, Metacycline can cause an increase in the absorption of Digoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N07BC02, methadone, Methadone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06BA03, methamphetamine, Metamfetamine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, The serum concentration of Digoxin can be increased when it is combined with Methimazole.]
[L01BA04, pemetrexed, Digoxin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02BG08, ziconotide, Digoxin may increase the arrhythmogenic activities of Ziconotide.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Methotrimeprazine.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the hypokalemic activities of Digoxin.]
[C02AB01, methyldopa, Methyldopa may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V04CG05, methylene blue, Methylene blue may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Digoxin.]
[D07AC14, methylprednisolone aceponate, The risk or severity of adverse effects can be increased when Methylprednisolone aceponate is combined with Digoxin.]
[G03EK01, methyltestosterone, Methyltestosterone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A03FA01, metoclopramide, The serum concentration of Digoxin can be decreased when it is combined with Metoclopramide.]
[C03BA08, metolazone, Metolazone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C07AB02, metoprolol, Metoprolol may increase the arrhythmogenic activities of Digoxin.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Metronidazole.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01BB02, mexiletine, Mexiletine may increase the arrhythmogenic activities of Digoxin.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Parnaparin.]
[N05CD08, midazolam, Midazolam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01CA17, midodrine, Digoxin may increase the bradycardic, atrioventricular blocking (AV block), and arrhythmogenic activities of Midodrine.]
[G03XB01, mifepristone, Mifepristone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Tinzaparin.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of hyperkalemia can be increased when Valsartan is combined with Digoxin.]
[J01AA08, minocycline, Minocycline can cause an increase in the absorption of Digoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[J01FA11, miocamycin, The serum concentration of Digoxin can be increased when it is combined with Miocamycin.]
[L01DB07, mitoxantrone, Digoxin may decrease the cardiotoxic activities of Mitoxantrone.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01BD01, amiodarone, The serum concentration of Digoxin can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02AA01, morphine, The serum concentration of Digoxin can be increased when it is combined with Morphine.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Certolizumab pegol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B02BX05, eltrombopag, The excretion of Digoxin can be decreased when combined with Eltrombopag.]
[G04BA01, ammonium chloride, Ammonium chloride may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Digoxin.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of Cardiac Arrhythmia can be increased when Vecuronium is combined with Digoxin.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Amodiaquine.]
[G04CA04, silodosin, The serum concentration of Digoxin can be increased when it is combined with Silodosin.]
[G03XC01, raloxifene, The excretion of Raloxifene can be decreased when combined with Digoxin.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Amoxapine.]
[C07AA12, nadolol, Digoxin may increase the arrhythmogenic activities of Nadolol.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V03AB15, naloxone, Naloxone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01GA01, naphazoline, The risk or severity of Cardiac Arrhythmia can be increased when Naphazoline is combined with Digoxin.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A10BG01, troglitazone, Troglitazone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AX21, duloxetine, Duloxetine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01CD02, docetaxel, Digoxin may decrease the cardiotoxic activities of Docetaxel.]
[S03AA01, neomycin, The serum concentration of Digoxin can be decreased when it is combined with Neomycin.]
[N01AH06, remifentanil, Digoxin may increase the bradycardic activities of Remifentanil.]
[A10BX02, repaglinide, Digoxin may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[C01CX08, levosimendan, Digoxin may increase the arrhythmogenic activities of Levosimendan.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L03AX16, plerixafor, Plerixafor may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01AA23, netilmicin, Netilmicin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Desvenlafaxine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C09CA07, telmisartan, The serum concentration of Digoxin can be increased when it is combined with Telmisartan.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[H05BX02, paricalcitol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Digoxin.]
[C01CE01, inamrinone, Amrinone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01XX01, amsacrine, Digoxin may decrease the cardiotoxic activities of Amsacrine.]
[C08CA04, nicardipine, Digoxin may increase the arrhythmogenic activities of Nicardipine.]
[C08CA05, nifedipine, The serum concentration of Digoxin can be increased when it is combined with Nifedipine.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C08CA06, nimodipine, Digoxin may increase the arrhythmogenic activities of Nimodipine.]
[C08CA07, nisoldipine, Digoxin may increase the arrhythmogenic activities of Nisoldipine.]
[C08CA08, nitrendipine, Digoxin may increase the arrhythmogenic activities of Nitrendipine.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01CA03, norepinephrine, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Digoxin.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Norfloxacin.]
[C02KX01, bosentan, Bosentan may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Nortriptyline.]
[A16AX07, sapropterin, Sapropterin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G02CA02, nylidrin, Digoxin may increase the arrhythmogenic activities of Nylidrin.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Reviparin.]
[G01AA01, nystatin, The excretion of Digoxin can be decreased when combined with Nystatin.]
[H01CB02, octreotide, The serum concentration of Digoxin can be decreased when it is combined with Octreotide.]
[S02AA16, ofloxacin, Digoxin may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[J01FA05, oleandomycin, The serum concentration of Digoxin can be increased when it is combined with Oleandomycin.]
[A02BC01, omeprazole, The serum concentration of Digoxin can be increased when it is combined with Omeprazole.]
[N02AA02, opium, Opium may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01AC01, ouabain, The excretion of Ouabain can be decreased when combined with Digoxin.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Oxolinic acid.]
[C07AA02, oxprenolol, Digoxin may increase the arrhythmogenic activities of Oxprenolol.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Digoxin can be decreased when used in combination with Oxymetazoline.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[S01AA04, oxytetracycline, Oxytetracycline can cause an increase in the absorption of Digoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Digoxin.]
[V04CH30, 4-aminohippuric acid, The excretion of Digoxin can be decreased when combined with Aminohippuric acid.]
[J04AA01, aminosalicylic acid, The serum concentration of Digoxin can be decreased when it is combined with Aminosalicylic acid.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Danaparoid.]
[M03AC01, pancuronium, The risk or severity of Cardiac Arrhythmia can be increased when Pancuronium is combined with Digoxin.]
[J04AB30, capreomycin, Capreomycin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Papaverine.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Paramethasone is combined with Digoxin.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Pefloxacin.]
[G04BD11, fesoterodine, Fesoterodine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C07AA23, penbutolol, Penbutolol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AG03, penfluridol, Digoxin may increase the arrhythmogenic activities of Penfluridol.]
[M01CC01, penicillamine, The serum concentration of Digoxin can be decreased when it is combined with Penicillamine.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Digoxin.]
[J01CE09, penicillin G procaine, Procaine benzylpenicillin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05CA01, pentobarbital, Pentobarbital may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01XX08, pentostatin, Digoxin may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pentoxifylline may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C08EX02, perhexiline, Digoxin may increase the arrhythmogenic activities of Perhexiline.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Pheniramine.]
[N03AA02, phenobarbital, Phenobarbital may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N03AB02, phenytoin, The serum concentration of Digoxin can be decreased when it is combined with Phenytoin.]
[S01AE05, levofloxacin, Levofloxacin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C08CX01, mibefradil, Digoxin may increase the arrhythmogenic activities of Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Pimozide.]
[C07AA03, pindolol, Pindolol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AA05, atorvastatin, The serum concentration of Digoxin can be increased when it is combined with Atorvastatin.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J05AE01, saquinavir, The serum concentration of Digoxin can be increased when it is combined with Saquinavir.]
[N06BX03, piracetam, Piracetam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Eprosartan.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Grepafloxacin.]
[C09CA04, irbesartan, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Irbesartan.]
[L02BG03, anastrozole, Digoxin may decrease the cardiotoxic activities of Anastrozole.]
[A06AD15, polyethylene glycols, The serum concentration of Digoxin can be decreased when it is combined with Polyethylene glycol.]
[C03AA05, polythiazide, Polythiazide may increase the hypokalemic activities of Digoxin.]
[J05AE03, ritonavir, The bioavailability of Digoxin can be increased when combined with Ritonavir.]
[A10BH03, saxagliptin, Saxagliptin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V03AB21, potassium iodide, The serum concentration of Digoxin can be increased when it is combined with Potassium Iodide.]
[C10AA08, pitavastatin, Digoxin may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C07AB01, practolol, Digoxin may increase the arrhythmogenic activities of Practolol.]
[C01BA08, prajmaline, Digoxin may increase the arrhythmogenic activities of Prajmaline.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Digoxin.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Digoxin.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Antazoline.]
[C01DX02, prenylamine, Digoxin may increase the arrhythmogenic activities of Prenylamine.]
[P01BA03, primaquine, The serum concentration of Digoxin can be increased when it is combined with Primaquine.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Probucol.]
[C01BA02, procainamide, Digoxin may increase the arrhythmogenic activities of Procainamide.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Prochlorperazine.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Promazine.]
[R06AD02, promethazine, Promethazine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C01BC03, propafenone, The serum concentration of Digoxin can be increased when it is combined with Propafenone.]
[A03AB05, propantheline, The serum concentration of Digoxin can be increased when it is combined with Propantheline.]
[R06AX26, fexofenadine, The serum concentration of Digoxin can be increased when it is combined with Fexofenadine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Propofol.]
[C07AA05, propranolol, Digoxin may increase the arrhythmogenic activities of Propranolol.]
[H03BA02, propylthiouracil, The serum concentration of Digoxin can be increased when it is combined with Propylthiouracil.]
[N02CC04, rizatriptan, Rizatriptan may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[B01AC09, epoprostenol, The serum concentration of Digoxin can be increased when it is combined with Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Digoxin.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Aripiprazole.]
[N07XX07, dalfampridine, Dalfampridine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[P02CC01, pyrantel, Pyrantel may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Digoxin.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Mepyramine.]
[C01BA01, quinidine, The serum concentration of Digoxin can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Digoxin can be increased when it is combined with Quinine.]
[D07AC10, diflorasone, The risk or severity of adverse effects can be increased when Diflorasone is combined with Digoxin.]
[A02BA02, ranitidine, Ranitidine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02AA01, rescinnamine, The risk or severity of hyperkalemia can be increased when Digoxin is combined with Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Digoxin.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J04AB02, rifampin, The serum concentration of Digoxin can be decreased when it is combined with Rifampicin.]
[J01AA09, rolitetracycline, Rolitetracycline can cause an increase in the absorption of Digoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[J01FA06, roxithromycin, The serum concentration of Digoxin can be increased when it is combined with Roxithromycin.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A07EC01, sulfasalazine, The serum concentration of Digoxin can be decreased when it is combined with Sulfasalazine.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N05CA06, secobarbital, Secobarbital may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[J01GB08, sisomicin, Sisomicin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Sodium fluoride may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[V04CC01, sorbitol, Sorbitol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C07AA07, sotalol, Sotalol may increase the arrhythmogenic activities of Digoxin.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Digoxin.]
[J01FA02, spiramycin, The serum concentration of Digoxin can be increased when it is combined with Spiramycin.]
[C03DA01, spironolactone, The serum concentration of Digoxin can be increased when it is combined with Spironolactone.]
[N05CC01, chloral hydrate, Chloral hydrate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Valproic acid.]
[D11AX24, deoxycholic acid, Deoxycholic acid may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Digoxin.]
[D07AB11, hydrocortisone probutate, The risk or severity of adverse effects can be increased when Hydrocortisone probutate is combined with Digoxin.]
[L01CD03, paclitaxel poliglumex, Digoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[H02CA04, levoketoconazole, Levoketoconazole may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A05AA02, ursodiol, Ursodeoxycholic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[A12AA11, calcium pangamate, Calcium pangamate may increase the arrhythmogenic and cardiotoxic activities of Digoxin.]
